Results 61 to 70 of about 39,430 (282)
Inhibitors of C5 complement enhance vaccinia virus oncolysis [PDF]
Genetically engineered tumor-selective vaccinia virus (VV) has been demonstrated to be a highly effective oncolytic agent, but immune clearance may limit its therapeutic potential. As previously demonstrated, immunosuppression can lead to significant enhancement of viral recovery and therapeutic effect, but the magnitude of complement-mediated viral ...
D, Magge +5 more
openaire +2 more sources
ABSTRACT Acute pancreatitis (AP) begins with pancreatic local inflammation, leading to the onset of systemic inflammatory response syndrome (SIRS), followed by compensatory anti‐inflammatory response syndrome (CARS), which causes immune paralysis and higher mortality rate.
Liwei Liu +15 more
wiley +1 more source
Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, hematologic disease characterized by complement-mediated hemolysis, thrombosis, and various degrees of bone marrow dysfunction.
Raymond S.M. Wong
doaj +1 more source
Fluorescent BODIPY‐conjugated thiosemicarbazone ligands and their Ga(III), In(III), and Fe(III) complexes, inspired by Triapine, are developed as theranostic agents. Multiphoton FLIM and confocal microscopy in cancer cells and zebrafish reveal real‐time uptake, mitochondrial localisation, and whilst spectroscopic assays indicated preserved complex ...
Megan J. Green +15 more
wiley +1 more source
Complement C5 inhibitors bring an increased risk for Neisseria infections. A novel complement C3 inhibitor, pegcetacoplan, was recently approved to treat paroxysmal nocturnal hemoglobinuria, a condition commonly treated with complement C5 inhibitors. We
Leo Starck +8 more
doaj +1 more source
Development and characterization of novel anti‐C5 monoclonal antibodies capable of inhibiting complement in multiple species [PDF]
Over the last decade there has been an explosion in complement therapies; one third of the drugs in the clinic or in development target C5 protein. Eculizumab, a monoclonal antibody (mAb) that binds C5 and blocks its cleavage by the convertase, is the ...
Taylor, Philip R. +5 more
core +1 more source
Effects of Complement C5 on Apoptosis in Experimental Autoimmune Encephalomyelitis [PDF]
Abstract Complement activation is involved in the initiation of Ab-mediated inflammatory demyelination in experimental autoimmune encephalomyelitis (EAE). At a sublytic dose, the C5b-9 membrane attack complex protects oligodendrocytes (OLG) from apoptosis.
Teodora, Niculescu +7 more
openaire +2 more sources
Oligonucleotide‐based fluorescence in situ hybridization probes were developed in the model citrus species Citrus maxima. These probes were applied to comparative karyotyping across 14 species in the Rutaceae family. This analysis revealed chromosomal evolution in lineages that diverged from Citrus nearly 52 million years ago.
Li He +9 more
wiley +1 more source
In glaucoma, studies revealed an involvement of the complement system. In an experimental autoimmune glaucoma model, immunization with an optic nerve homogenate antigen (ONA) led to retinal ganglion cell (RGC) loss, while intraocular pressure (IOP ...
Sabrina Reinehr +8 more
doaj +1 more source
(A) TPP-2799 alone (700 nM). (B) TPP-2799 (700 nM) plus complement component C5 (400 nM). (C) complement component C5 alone (400 nM). (EPS)
Josh Cone (15332831) +5 more
core +1 more source

